Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions
Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes.
LANTHEUS HOLDINGS INC was identified as an affordable growth stock. NASDAQ:LNTH is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
LANTHEUS HOLDINGS INC has a stellar value proposition. NASDAQ:LNTH not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQLNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board’s Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus’ strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
Based on a technical and fundamental analysis of NASDAQ:LNTH we ask: Is LANTHEUS HOLDINGS INC (NASDAQLNTH) on the Verge of a Major Breakout as a Strong Growth Stock?
Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease
Short-term market predictions are fun, but rarely worth investing in. Here are two stocks we think will be winners no matter what happens with the market in 2025.
